ArticleOphthalmology and therapy2020

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial.

Praveen J Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.